Skip to main content
SpringerLink
Log in

Traitement adjuvant et cancer du sein surexprimant HER2

  • Chapter
Le cancer du sein

Part of the book series: Oncologie pratique ((ONCOLPRAT))

  • 536 Accesses

Abstrait

Le développement du trastuzumab, anticorps monoclonal humanisé anti-HER2, a débuté en 1984 avec ľidentification de ľoncogène HER2 (1), rapidement suivie par son clonage (2, 3) et par la démonstration qu’un anticorps monoclonal dirigé contre le produit de ľoncogène — en ľoccurrence le récepteur HER2 — pouvait inhiber la croissance des cellules transformées HER2 (4). Dans le même temps, la recherche translationnelle prouvait la corrélation entre ľamplification du gène HER2, présente dans 25 à 30% des cancers du sein, et un mauvais pronostic (5). Ľimpact clinique a été établi dès 2001, en phase métastatique, avec une amélioration de la survie des patientes avec cancer du sein HER2 positif grâce à la combinaison avec la chimiothérapie (6), et confirmé de façon particulièrement impressionnante en phase adjuvante en 2005 avec les résultats de cinq études randomisées distinctes (7–10), permettant toutes ďobtenir une réduction du risque relatif de rechute de 50%, chiffre rarement atteint dans ľhistoire des essais adjuvants pour le cancer mammaire. Ces cinq études cliniques adjuvantes publiées ou rapportées, c’est-à-dire ľétude HERA (7, 8), ľanalyse poolée (9) des deux études nord-américaines NSABP-B31 et NCCTG/N9831, ľétude BCIRG 006 (10, 11) et ľétude FinHER (12), sont analysées et discutées dans ce chapitre.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Schechter AL, Stern DF, Vaidyanathan L et al. (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513–6

    Article  PubMed  CAS  Google Scholar 

  2. Semba K, Kamata N, Toyoshima K, Yamamoto T (1985) A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82: 6497–501

    Article  PubMed  CAS  Google Scholar 

  3. Coussens L, Yang-Feng TL, Liao YC et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132–9

    Article  PubMed  CAS  Google Scholar 

  4. Drebin JA, Link VC, Weinberg RA, Greene MI (1986) Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 83: 9129–33

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Clark GM, Wong SG et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–82

    Article  PubMed  CAS  Google Scholar 

  6. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–92

    Article  PubMed  CAS  Google Scholar 

  7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659–72

    Article  PubMed  CAS  Google Scholar 

  8. Smith I, Procter M, Gelber RD et al. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer a randomised controlled trial. Lancet 369 (9555): 29–36

    Article  PubMed  CAS  Google Scholar 

  9. Romond EH, Perez EA, Bryant J et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–84

    Article  PubMed  CAS  Google Scholar 

  10. Slamon D, Eiermann W, Robert N et al. (2005) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in hER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res and Treat 94 (supplément 1): S5 (abst 1)

    Google Scholar 

  11. Slamon D, Eiermann W, Robert N et al. (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclosphosphamide followed by docetaxel (ACT) with doxorubicin and cyclosphosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Breast Cancer Res Treat 100 (Suppl 1): General Session 2 (abst 52)

    Google Scholar 

  12. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354(8): 809–20

    Article  PubMed  CAS  Google Scholar 

  13. Baselga J, Norton L, Albanell J et al. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–31

    PubMed  CAS  Google Scholar 

  14. Pegram M, Hsu S, Lewis G et al. (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241–51

    Article  PubMed  CAS  Google Scholar 

  15. Sparano JA, Wang M, Martino S et al. From the Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group (SWOG), Cancer and Acute Leukemia Group B (CALBG), and the North Central Cancer Treatment Group (NCCTG) (2005) Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199. Breast Cancer Res and Treat 94 (Sup 1): abst 48

    Google Scholar 

  16. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–48

    PubMed  CAS  Google Scholar 

  17. Vogel CL, Cobleigh MA, Tripathy D et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–26

    Article  PubMed  CAS  Google Scholar 

  18. Baselga J, Carbonell X, Castaneda-Soto NJ et al. (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–71

    Article  PubMed  CAS  Google Scholar 

  19. Leyland-Jones B, Gelmon K, Ayoub JP et al. (2003) Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21: 3965–71

    Article  PubMed  CAS  Google Scholar 

  20. Cardoso F, Piccart MJ, Durbecq V, Di Leo A (2002) Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3: 247–57

    Article  PubMed  CAS  Google Scholar 

  21. Kim C, Bryant J, Horne Z et al. (2005) Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Breast Cancer Res Treat 94 (Supp 1): abst 46

    Google Scholar 

  22. The HERA Study team (2005) Trastuzumab (H:Herceptin®) following adjuvant chemotherapy (C+) significantly improves disease-free-survival (DFS) in early breast cancer (BC) with HER2 overexpression: the HERA trial. Breast Cancer Res and Treat 94 (Supp 1): abst 11

    Google Scholar 

  23. M Neyt, A Albrecht, VF Cocquyt (2006) An Economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol 17: 381–90

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service ďoncologie médicale Institut Jules Bordet, Université Libre de Bruxelles, Boulevard Waterloo 121, 1000, Bruxelles, Belgique

    C. Bernard-Marty & M. Piccart-Gebhart

Authors
  1. C. Bernard-Marty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Piccart-Gebhart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France

About this chapter

Cite this chapter

Bernard-Marty, C., Piccart-Gebhart, M. (2007). Traitement adjuvant et cancer du sein surexprimant HER2. In: Le cancer du sein. Oncologie pratique. Springer, Paris. https://doi.org/10.1007/978-2-287-36073-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-36073-2_10

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-36071-8

  • Online ISBN: 978-2-287-36073-2

Publish with us

Policies and ethics

Search

Navigation